Sec Form 4 Filing - Jagpal Sukhi @ Sierra Oncology, Inc. - 2022-07-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jagpal Sukhi 2. Issuer Name and Ticker or Trading Symbol Sierra Oncology, Inc. [ SRRA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110 3. Date of Earliest Transaction (MM/DD/YY) 07/01/2022 (Street) SAN MATEO, CA94404 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 122.2 07/01/2022 D 3,859 ( 1 ) 03/18/2025 Common Stock 3,859 $ 0( 2 ) 0 D Stock Option (right to buy) $ 263.2 07/01/2022 D 1,218 ( 3 ) 03/08/2026 Common Stock 1,218 $ 0( 2 ) 0 D Stock Option (right to buy) $ 72.8 07/01/2022 D 4,200 ( 4 ) 09/30/2026 Common Stock 4,200 $ 0( 2 ) 0 D Stock Option (right to buy) $ 58 07/01/2022 D 1,750 ( 5 ) 03/06/2027 Common Stock 1,750 $ 0( 2 ) 0 D Stock Option (right to buy) $ 94.4 07/01/2022 D 4,509 ( 6 ) 03/06/2028 Common Stock 4,509 $ 0( 2 ) 0 D Stock Option (right to buy) $ 78.4 07/01/2022 D 5,000 ( 7 ) 03/04/2029 Common Stock 5,000 $ 0( 2 ) 0 D Stock Option (right to buy) $ 13.31 07/01/2022 D 94,113 ( 8 ) 02/25/2030 Common Stock 94,113 $ 0( 9 ) 0 D Stock Option (right to buy) $ 12.15 07/01/2022 D 49,000 ( 10 ) 08/12/2030 Common Stock 49,000 $ 0( 9 ) 0 D Stock Option (right to buy) $ 12.15 07/01/2022 D 5,887 ( 11 ) 08/12/2030 Common Stock 5,887 $ 0( 9 ) 0 D Stock Option (right to buy) $ 16.73 07/01/2022 D 30,000 ( 12 ) 03/15/2031 Common Stock 30,000 $ 0( 9 ) 0 D Stock Option (right to buy) $ 31.54 07/01/2022 D 50,000 ( 13 ) 03/14/2032 Common Stock 50,000 $ 0( 9 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jagpal Sukhi C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DR., SUITE 110 SAN MATEO, CA94404 Chief Financial Officer Signatures /s/ Mary Christina Thomson, Attorney-In-Fact for Sukhi Jagpal 07/01/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option fully vested on February 2, 2019. ( 2 )Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. ( 3 )The option fully vested on January 1, 2020. ( 4 )The option fully vested on September 30, 2019. ( 5 )The option fully vested on January 1, 2021. ( 6 )The option fully vested on January 1, 2022. ( 7 )The option vested as to 25% of the tota l shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. ( 8 )The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. ( 9 )Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. ( 10 )On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. ( 11 )The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. ( 12 )The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. ( 13 )The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.